Apimeds

What Apimeds does

Apimeds (아피메즈) is a South Korean life science and diversified-operations company established in September 2003 as a subsidiary of Inscobee (인스코비, KOSPI: 006490). Its core business is the development and commercialization of Apitoxin (아피톡신), a standardized bee venom (apitoxin) pharmaceutical extracted via proprietary REM (macroporous resin) and NAS (oral absorption enhancement) platform technologies. Apitoxin was approved by Korea's MFDS in May 2003 as Korea's first natural new drug and the 6th new drug overall, and is currently in US FDA Phase 3 clinical development for osteoarthritis (Phase 3 completed April 2018) and multiple sclerosis (Phase 3 IND approved June 2018). The company has secured bee venom therapy patents in Korea, Japan, and the US.

Beyond the bio/pharma segment, Apimeds operates through its parent Inscobee in three additional business areas: a Smart Grid business selling PLC modems, DCUs, IoT-PLC/Wi-SUN modems, and meter gateways into KEPCO's AMI infrastructure; an MVNO service delivered through subsidiary Free Telecom leasing capacity from SKT, KT, and LGU+; and a Distribution business covering cosmetics (Dermicos with FGF7, Bee Plasty, Heama Beauty health supplements) and watches (Beluga, Black Eagles, Dolphin) via 2,500+ retail outlets. Apimeds also provides analytical research, formulation development, and quality testing services for pharmaceutical clients.

In 2020 Apimeds established a US subsidiary (APUS) and research institute in Seoul's Geumcheon-gu. APUS listed on NYSE American in May 2025 (raising approximately $13.5M) and entered a CRO contract with Prevail InfoWorks to initiate FDA Phase 3 trials, targeting First Patient In by January 2026. In December 2025 APUS completed a merger with MindWave Innovations Inc., transferring 90.9% ownership to MindWave shareholders, introducing a $100M PIPE and a convertible note facility of up to $120.9M, and reshaping leadership with Dr. Vin Menon as CEO. The bio business is planned to be spun into a new subsidiary, Lokahi Therapeutics, Inc.

Name

Apimeds

Legal name

아피메즈(주)

Website

https://apimeds.co.kr

Company type

Private

Founded year

2003

Operating status

Operating

Short description

Apimeds is a South Korean life sciences company (subsidiary of Inscobee) developing Apitoxin, a bee venom-based pharmaceutical in US FDA Phase 3 trials for osteoarthritis and multiple sclerosis, and operating adjacent smart grid, MVNO, and consumer distribution businesses.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals / Natural Product Drugs

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

akta.pro secondary industries

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Biologic API/Drug Substance Manufacturing Services (HLAAAKAA)

Keywords

• Bee venom pharmaceuticals
• Natural product drugs
• Smart grid PLC systems
• MVNO telecom services
• Biotherapeutic treatments

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales (Apitoxin): Sale of apitoxin as prescription drug for osteoarthritis and pain treatment. Currently approved in Korea as a specialty medicine and under clinical development in the US for multiple sclerosis and osteoarthritis.
2. Cosmetic and Health Functional Food Distribution: Distribution of high-functional cosmetic brands including Dermicos (FGF7 growth factor), Bee Plasty (bee venom), Heama Beauty (seahorse-based health supplement for menopausal women), and various watch brands
3. MVNO Communication Services: Mobile Virtual Network Operator service utilizing networks of SKT, KT, and LGU+ to provide affordable communication services to consumers through subsidiary Free Telecom
4. Smart Grid Products (PLC Modems and Equipment): Sale of watt-hour meter modems, Data Central Units (DCU), PLC modems, IoT-PLC modems, Wi-SUN modems, and C-SMGW meter gateways for KEPCO AMI system construction

Go-to-market motion1 record

Distribution channels5 records

Marketing channels3 records

Core offering

Apimeds fundamentally develops and sells Apitoxin, a standardized bee venom (apitoxin) prescription pharmaceutical that is Korea's first MFDS-approved natural new drug (6th new drug overall), using proprietary REM and NAS platform technologies. The company also operates Smart Grid PLC hardware, MVNO telecom services via subsidiary Free Telecom, and distributes cosmetics, watches, and health functional foods through separate business segments. All four segments operate under the parent Inscobee (KOSPI: 006490).

Product overview

Apimeds is a life science company specializing in natural product pharmaceuticals and biotech research. The core product is Apitoxin, Korea's first and only MFDS-approved natural bee venom drug (6th new drug in Korea), currently in US FDA Phase 3 clinical trials for multiple sclerosis and osteoarthritis. The company operates across multiple business segments: Bio Business (bee venom pharmaceuticals, stem cell research, tissue engineering, genetic engineering, cancer diagnostics), Smart Grid (PLC-based power communication systems including K2 chips and DCU devices), MVNO (budget mobile services), and Distribution (cosmetics including Dermicos and Bee Plasty, watches including Dolphin, Beluga, and Black Eagles brands). The company also provides analytical research and medicine research services for pharmaceutical development. Founded in 2003, Apimeds holds patents for bee venom therapy in Korea, Japan, and the US, and has a US subsidiary (APUS) listed on NYSE America.

Differentiator

Problem solved

Functional benefit

Brands

• Apitoxin (아피톡신): Natural bee venom-based prescription drug; first natural new drug approved by MFDS in Korea and the 6th new drug in Korea. Used for pain treatment and under clinical development for osteoarthritis and multiple sclerosis.

Products and services

• Apitoxin (아피톡신) A standardized bee venom (apitoxin) prescription drug developed using REM extraction technology and NAS platform technology. Korea's first and only MFDS-approved natural new drug, originally approved for osteoarthritis pain treatment. Currently undergoing US FDA Phase 3 clinical trials for multiple sclerosis and osteoarthritis. Distributed in Korea as a specialty prescription drug via licensing partner Guju Pharmaceutical.
• Smart Grid / PLC Products Power Line Communication (PLC) based smart grid system products including K2 Chip (PLC communication chip), Data Central Unit (DCU), Bridge/Repeater, PLC attenuator, IoT-PLC modem, Wi-SUN modem, C-SMGW meter gateway, and PLC modems for KEPCO AMI system construction. Uses NMS (Network Management System) for the Korean-type PLC globalization and smart grid implementation.
• MVNO Communication Service Mobile Virtual Network Operator service provided through subsidiary Free Telecom, leveraging the networks of three domestic carriers (SKT, KT, LGU+) to deliver affordable mobile communication services to consumers. Includes USIM-only signup options and distribution through SIM Square retail locations.
• Analytical Research Service Drug equivalence testing (comparative dissolution test), drug stability testing, analytical method development and validation. Services include content test, confirmation test, purity test, dissolution test, and residual solvent test. Provided by Apimeds Research Institute to support quality control and regulatory submissions.
• Medicine Research Service (Formulation Development) Development of various formulations with analysis and production consignment options. Supports CTD Module 2 and 3 documentation, stability testing, and regulatory permission applications. Equipment includes hardness tester, friability tester, disintegration instrument, coating machine, tablet machine, and PTP packing machine.
• Cell Therapeutics / Cell Therapy Stem cell-based therapies and cell reprogramming technologies developed through investment and partnership with Cell Therapeutics Bio, including HGF protein and exosome-based treatments for regenerative medicine applications in pharmaceutical and cosmetic applications.
• ExTT-101 Female Medical Device Urinary incontinence test treatment and biofeedback training device for pelvic floor and vaginal muscles. Patents registered in Korea (No. 0710908, 2007), Japan (No. 4153027, 2008), and China (No. 570601, 2009). GMP-certified as a Korean medical device manufacturing facility in 2008.
• Dermicos (Cosmetic Brand) Premium bioceutical cosmetic brand containing patented growth factor FGF7 marketed as 100% consistent with skin DNA, targeted at anti-aging skincare consumers.
• Bee Plasty (Cosmetic Brand) High-potential bioceutical cosmetic brand combining bee venom (patented new bio-ingredient from 40 years of R&D) with skin science technology to deliver natural bio-ingredient effects for skincare consumers.
• Heama Beauty (Health Functional Food) Health functional food for menopausal women, made with world's first antibiotic-free natural cultured seahorse (Jeju) as raw material. Targeted at consumers needing menopausal health support.
• Dolphin (Watch Brand) Representative brand of domestic leisure sports and digital watches with simple design, 100m water resistance, and multi-function features. Distributed through over 2,500 retail stores nationwide.
• Beluga (Watch Brand) Trendy and unique fashion jewelry watch brand combining genuine Swarovski crystals and jewelry with elegant design. Distributed through over 2,500 retail stores nationwide.
• Black Eagles (Watch Brand) Korean pilot watch brand exclusively produced using the mark and logo of the Korean Air Force Special Flight Team (239th Squadron) and T-50B aircraft design elements. Distributed through over 2,500 retail stores nationwide.

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered flagship, core and minor.

• MindWave Innovations Inc.flagshipStrategic or Co-development Partner · 1 December 2025Merger completed December 1, 2025 integrating biotech growth with AI-driven digital treasury yield generation backed by $100M PIPE. MindWave shareholders acquired 90.9% stake post-merger. New leadership includes Dr. Vin Menon as CEO and Amir Dossal as board member.
• Prevail InfoWorks Inc.coreImplementation/ SI/ Consulting Partner · 1 June 2025Clinical Research Organization (CRO) providing integrated solutions for FDA clinical trials. Prevail was selected as CRO for APUS Phase 3 clinical trials for osteoarthritis treatment. Prevail also participated as investor in APUS NYSE listing and is currently a shareholder.
• Cell Therapeutics Bio (셀라퓨틱스바이오)coreStrategic or Co-development Partner · 1 January 2021Cell therapy specialist company developing cell therapeutics based on somatic cell reprogramming technology. Apimeds invested in and signed business agreement to access HGF protein and exosome technology from cell reprogramming processes for pharmaceutical and cosmetic applications.
• Guju Pharmaceutical (구주제약)coreChannel Partner/ Reseller/ DistributorLicensing partner holding approval rights for Apitoxin distribution in Korea as osteoarthritis pain treatment drug
• Free Telecom (프리텔레콤)coreChannel Partner/ Reseller/ DistributorSubsidiary MVNO operator leasing network from three major carriers (SKT, KT, LGU+) to provide affordable mobile communication services
• SIM Square (심스퀘어)minorChannel Partner/ Reseller/ DistributorOverseas SIM distribution company offering high-quality local overseas USIMs from mobile carriers around the world, available for international travelers
• Lokahi Therapeutics, Inc.coreStrategic or Co-development PartnerBio subsidiary established to house Apimeds' biotech business including Apitox development after merger with MindWave

Scale indicators8 records

Recent moves11 records

Expansion highlights5 records

Broad incumbents

• Biogen: Global specialty biopharmaceutical company with the leading multiple sclerosis franchise (Tysabri, Tecfidera, Vumerity, Avonex). Direct incumbent in the MS indication that Apimeds is targeting with Apitoxin Phase 3, and a benchmark for what successful MS franchise economics look like.
• Novartis: Large pharmaceutical company with a leading multiple sclerosis franchise including Gilenya and Kesimpta. Represents the competitive landscape Apimeds would face in MS and illustrates what an established commercial footprint in autoimmune neurology looks like.
• Roche: Global pharmaceutical leader with Ocrevus, the highest-revenue MS therapy, and broad immunology/inflammation pipeline. Comparable as a large incumbent that Apimeds' Apitoxin innovation would need to differentiate against in MS and inflammation indications.
• EMD Serono (Merck KGaA): Biopharmaceutical division of Merck KGaA with a multiple sclerosis franchise including Mavenclad and Rebif, focused on specialty immunology. Relevant as another established competitor in the MS indication that Apimeds is targeting with Apitoxin.
• Sanofi: Global pharmaceutical company with established MS franchise (Aubagio, Lemtrada) and a strong specialty/immunology footprint. Comparable as a broad incumbent competing in Apimeds' target indications of multiple sclerosis and inflammatory pain conditions.

Direct peers

• Daewoong Pharmaceutical: Korean innovative pharmaceutical company with a comparable trajectory of developing novel biologics and small molecules and pursuing FDA approvals from a Korea-headquartered base (e.g., nab-paclitaxel, botulinum toxin). Like Apimeds, Daewoong runs Korean-originated clinical programs targeting US and global specialty pharma markets.
• Hanmi Pharmaceutical: Korean specialty pharmaceutical company developing novel biologics and innovative small molecules with global out-licensing deals. Hanmi's portfolio of internally-discovered candidates progressing through US clinical trials makes it a strong comparable for Apimeds' Apitoxin Phase 3 strategy.

Regional players

• Yuhan Corporation: Korean pharmaceutical company with a mix of branded innovative drugs, generics, and consumer health products, with growing US presence through licensing and FDA filings. Comparable as a Korean pharma operating across both innovative pharma and consumer/distribution businesses similar to Inscobee/Apimeds' diversified structure.
• Celltrion: Korea-based biopharmaceutical manufacturer specializing in biosimilars and biologics with global commercialization including US FDA approvals. Comparable as a Korean-headquartered biologics developer that has scaled a manufacturing and clinical platform internationally, similar in geographic and category origin to Apimeds.

Emerging players

• TG Therapeutics: Smaller clinical-to-commercial biopharma company that brought Briumvi (ublituximab) to market in multiple sclerosis. Comparable as an emerging player that successfully navigated MS regulatory and commercial hurdles, providing a relevant scale and trajectory benchmark for Apimeds.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apimeds